Wearable Light Therapy Treats Psoriasis at Home
By HospiMedica International staff writers Posted on 03 Aug 2017 |
Image: A wearable device can treat mild psoriasis with blue light (Photo courtesy of Philips Healthcare).
A novel blue light emitting diode (LED) device induces natural, drug-free processes in the skin that can significantly reduce the symptoms of mild psoriasis vulgaris.
The Royal Philips (Philips; Amsterdam, The Netherlands) BlueControl wearable device is comprised of high intensity, pulsed blue LEDs that are optimized to deliver phototherapy for mild to moderate plaque psoriasis. The 40 LEDs are set into the small, battery-driven device secured by textile fixation straps to the affected body part, such as the arms, legs, elbows, or knees. Once in position, the ultraviolet (UV) free blue light triggers natural processes in the skin that ease symptoms of psoriasis, including redness and scaling. Treatment sessions are timed for 30 minutes.
In two consecutive clinical studies in partnership with University Hospital of Aachen (Germany), patients were treated for a period of three months to investigate the efficacy and safety of the device. Overall, 84% of the patients showed an improvement in plaque symptoms (thickness, redness, and scaling) as measured by the Local Psoriasis Area Severity Index (PASI), when compared to baseline; in some cases, complete disappearance of plaque was observed. Furthermore, no negative side effects were recorded in the studies.
“We aim to improve people's health with a broad portfolio of proven therapy solutions to enable patients with chronic conditions to manage their health at home,” said David Aubert, general manager of the Royal Philips Light & Health business. “Philips BlueControl is a clinically proven light therapy device that can be easily integrated into a patient's daily routine.”
Psoriasis is a chronic skin condition with intermittent relapses characterized by patches, papules, and plaques. Plaque psoriasis is the most common form, and typically manifests as red and white scaly patches on the top layer of the skin, creating silvery-white painful, itchy lesions. Psoriasis is generally considered a genetic disease influenced by environmental factors, and affects approximately 1-2% of the world’s population. It been linked to a host of other health problems such as arthritis, inflammatory bowel disease (IBD), depression, obesity, hypertension, ischemic heart disease, and stroke.
The Royal Philips (Philips; Amsterdam, The Netherlands) BlueControl wearable device is comprised of high intensity, pulsed blue LEDs that are optimized to deliver phototherapy for mild to moderate plaque psoriasis. The 40 LEDs are set into the small, battery-driven device secured by textile fixation straps to the affected body part, such as the arms, legs, elbows, or knees. Once in position, the ultraviolet (UV) free blue light triggers natural processes in the skin that ease symptoms of psoriasis, including redness and scaling. Treatment sessions are timed for 30 minutes.
In two consecutive clinical studies in partnership with University Hospital of Aachen (Germany), patients were treated for a period of three months to investigate the efficacy and safety of the device. Overall, 84% of the patients showed an improvement in plaque symptoms (thickness, redness, and scaling) as measured by the Local Psoriasis Area Severity Index (PASI), when compared to baseline; in some cases, complete disappearance of plaque was observed. Furthermore, no negative side effects were recorded in the studies.
“We aim to improve people's health with a broad portfolio of proven therapy solutions to enable patients with chronic conditions to manage their health at home,” said David Aubert, general manager of the Royal Philips Light & Health business. “Philips BlueControl is a clinically proven light therapy device that can be easily integrated into a patient's daily routine.”
Psoriasis is a chronic skin condition with intermittent relapses characterized by patches, papules, and plaques. Plaque psoriasis is the most common form, and typically manifests as red and white scaly patches on the top layer of the skin, creating silvery-white painful, itchy lesions. Psoriasis is generally considered a genetic disease influenced by environmental factors, and affects approximately 1-2% of the world’s population. It been linked to a host of other health problems such as arthritis, inflammatory bowel disease (IBD), depression, obesity, hypertension, ischemic heart disease, and stroke.
Latest Critical Care News
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events
- AI Diagnostic Tool Guides Rapid Diagnosis and Prediction of Sepsis
- World's First AI-Powered Sepsis Alert System Detects Sepsis in One Minute
- Smartphone Magnetometer Uses Magnetized Hydrogel to Measure Biomarkers for Disease Diagnosis
- New Technology to Revolutionize Valvular Heart Disease Care